Crossbow Therapeutics
Updated: March 23, 2026
CEO - Briggs Morrison
Country: USA | Funding: $110.3M (+)
Founded: 2021
Website: https://www.crossbowtx.com
Crossbow Therapeutics develops antibody therapeutics to treat cancer. It identifies, validates and prioritizes the most promising cancer antigens for its T-Cell Receptor mimetic (TCRm) discovery efforts. Its lead candidate is T-cell engager CBX-250, designed to target a peptide human leukocyte antigen (pHLA) that’s found on myeloid cancer cells. The company is conducting trials which have enrolled patients with acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndromes and chronic myelomonocytic leukemia. Crossbow also develops other so-called T-Bolt immunotherapies, which use TCR-mimetic antibodies to target pHLA on cancer cells.
Founded: 2021
Website: https://www.crossbowtx.com
Crossbow Therapeutics develops antibody therapeutics to treat cancer. It identifies, validates and prioritizes the most promising cancer antigens for its T-Cell Receptor mimetic (TCRm) discovery efforts. Its lead candidate is T-cell engager CBX-250, designed to target a peptide human leukocyte antigen (pHLA) that’s found on myeloid cancer cells. The company is conducting trials which have enrolled patients with acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndromes and chronic myelomonocytic leukemia. Crossbow also develops other so-called T-Bolt immunotherapies, which use TCR-mimetic antibodies to target pHLA on cancer cells.
